Skip to main content

Chronic Cluster Headache

4
Pipeline Programs
6
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
EptinezumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05064397Completed131Est. Jun 2023
Prevail Therapeutics
1 program
1
Galcanezumab 300 mgPhase 31 trial
Active Trials
NCT02438826Completed240Est. Aug 2019
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
occipital nerve stimulationPhase 31 trial
Active Trials
NCT01151631Completed130Est. Mar 2019
electroCore
electroCoreNJ - Rockaway
1 program
1
GammaCorePhase 21 trial
Active Trials
NCT01701245Completed97Est. Oct 2014
Salvia BioElectronics
Salvia BioElectronicsNetherlands - Eindhoven
2 programs
PRIMUSN/A1 trial
The Salvia PRIMUS implantable neurostimulator SystemN/A1 trial
Active Trials
NCT05868044Active Not Recruiting5Est. Dec 2026
NCT07113470Recruiting10Est. Dec 2028
Teva
TevaIsrael - Petach Tikva
1 program
FremanezumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT02964338Terminated259Est. Jul 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
LundbeckEptinezumab
TevaFremanezumab
Prevail TherapeuticsGalcanezumab 300 mg
Medtronicoccipital nerve stimulation
electroCoreGammaCore
Salvia BioElectronicsThe Salvia PRIMUS implantable neurostimulator System
Salvia BioElectronicsPRIMUS

Clinical Trials (7)

Total enrollment: 872 patients across 7 trials

NCT05064397LundbeckEptinezumab

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Start: Sep 2021Est. completion: Jun 2023131 patients
Phase 3Completed
NCT02964338TevaFremanezumab

A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

Start: Jan 2017Est. completion: Jul 2018259 patients
Phase 3Terminated
NCT02438826Prevail TherapeuticsGalcanezumab 300 mg

A Study of Galcanezumab in Participants With Chronic Cluster Headache

Start: Jun 2015Est. completion: Aug 2019240 patients
Phase 3Completed
NCT01151631Medtronicoccipital nerve stimulation

Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache

Start: Oct 2010Est. completion: Mar 2019130 patients
Phase 3Completed
NCT01701245electroCoreGammaCore

Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care

Start: Oct 2012Est. completion: Oct 201497 patients
Phase 2Completed
NCT07113470Salvia BioElectronicsThe Salvia PRIMUS implantable neurostimulator System

Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache

Start: Mar 2026Est. completion: Dec 202810 patients
N/ARecruiting
NCT05868044Salvia BioElectronicsPRIMUS

REsponse to Combined SONS and ONS in Chronic Cluster headachE

Start: May 2023Est. completion: Dec 20265 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 872 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.